Quantcast

Latest Protease inhibitor Stories

2011-04-01 00:00:00

HUDDINGE, Sweden, April 1, 2011 /PRNewswire-FirstCall/ -- - Results Show Potent Antiviral Efficacy of Once Daily 150 mg TMC435 in Hepatitis C Patients Who Have Failed Earlier Treatment, Especially in Prior Null Responders, and Excellent Safety and Tolerability Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of...

2011-03-03 16:45:39

 A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo. Palumbo, a professor of pediatric medicine at Dartmouth Medical School and executive director of the Dartmouth-affiliated DarDar Pediatric program in Dar-es-Salaam, Tanzania, unveiled the latest findings of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT ) during the...

2011-02-18 04:48:00

HUDDINGE, Sweden, February 18, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started. Phase 3 Program in brief: - TMC435-C208 or QUEST-1 includes approximately 375...

2011-02-14 01:29:00

HUDDINGE, Sweden, February 14, 2011 /PRNewswire/ -- Highlights of the Collaboration: - Collaboration with Janssen Pharmaceutica N.V. Focused on Dengue Virus - Both Parties to Contribute 50:50 Resources to the Research Program - Strengthens Medivir's Presence in Infectious Diseases And Utilises Strong Know-How in the Discovery of Protease Inhibitor Drugs Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious...

2011-02-10 05:59:00

HUDDINGE, Sweden, February 10, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection. TMC649128 is a nucleoside NS5B polymerase inhibitor that has already demonstrated an attractive pre-clinical profile. It is anticipated that this profile would see TMC649128 be used...

2011-02-09 16:00:00

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs. IDX184, a liver-targeted HCV nucleotide prodrug The U.S. Food and Drug Administration (FDA) has verbally informed Idenix that the full clinical hold for IDX184 has been removed. The program has been placed on...

2011-02-04 07:30:14

(Ivanhoe Newswire) -- It's a well-known fact that children with HIV will need anti-HIV medicines for longer than adults.  A recent study ultimately questions which anti-HIV drugs to start children with and when to switch to a different one if the virus levels begin to increase.  These are questions that must be answered. Two types of drugs "” protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) "” are just as efficient as part of initial...

2010-12-08 00:00:44

New report from MedPredict includes thought leader discussion of key development activities in the HCV pipeline, including their perspectives on unmet needs and how compounds nearing approval are likely to address them. Scottsdale, AZ (PRWEB) December 7, 2010 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Hepatitis C Virus (HCV)," designed to provide...

2010-11-18 00:00:00

HUDDINGE, Sweden, November 18, 2010 /PRNewswire/ -- - Once Daily Novel Therapy in Treatment-Experienced Hepatitis C Patients Highlights of the Study TMC435 Added to Standard of Care: - Increased the response rates and antiviral efficacy, which progressed through to week 24 - Increased the number of patients with undetectable Hepatitis C Virus (HCV) levels through week 4, 12 and 24 - Safe and well tolerated Medivir AB (OMX: MVIR), the emerging...

2010-11-01 01:00:00

HUDDINGE, Sweden, November 1, 2010 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily. The study was conducted in...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.